1. |
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J, 2005, 26(4): 586-593.
|
2. |
Suzuki A, Kondoh Y. The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respir Investig, 2017, 55(2): 94-103.
|
3. |
Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med, 2018, 378(19): 1811-1823.
|
4. |
黄海, 郑臻, 陈依林, 等. 特发性肺纤维化合并肺气肿与未合并肺气肿患者的临床差异. 国际呼吸杂志, 2014, 34(4): 254-256.
|
5. |
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011, 183(6): 788-824.
|
6. |
Sugino K, Ishida F, Kikuchi N, et al. Comparison of clinical characteristics and prognostic factors of combined pulmonary fibrosis and emphysema versus idiopathic pulmonary fibrosis alone. Respirology, 2014, 19(2): 239-245.
|
7. |
Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest, 2013, 144(1): 234-240.
|
8. |
Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis, 2015, 7(4): 767-779.
|
9. |
Pepin EW, Verma N, Mehta HJ, et al. Combined pulmonary fibrosis and emphysema. Ann Am Thorac Soc, 2018, 15(1): 110-112.
|
10. |
Morse D, Rosas IO. Tobacco smoke-induced lung fibrosis and emphysema. Annu Rev Physiol, 2014, 76: 493-513.
|
11. |
Ryu JH, Colby TV, Hartman TE, et al. Smoking-related interstitial lung diseases: a concise review. Eur Respir J, 2001, 17(1): 122-132.
|
12. |
Papaioannou AI, Kostikas K, Manali ED, et al. Combined pulmonary fibrosis and emphysema: The many aspects of a cohabitation contract. Respir Med, 2016, 117: 14-26.
|
13. |
Malli F, Papakosta D, Antoniou K, et al. Combined pulmonary fibrosis and emphysema characteristics in a Greek cohort. ERJ Open Res, 2019, 5(1): 00014-2018.
|
14. |
Yoon HY, Kim TH, Seo JB, et al. Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology, 2019, 24(1): 55-62.
|
15. |
Çiftci F, Gülpınar B, Atasoy Ç, et al. Combined pulmonary fibrosis and emphysema: how does cohabitation affect respiratory functions?. Adv Med Sci, 2019, 64(2): 285-291.
|
16. |
Pecchio F, Rapellino M, Ricci E, et al. TA 4-SCC versus CEA sensitivity for lung cancer. Tumori, 1988, 74(4): 393-395.
|
17. |
Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem, 2002, 48(11): 1931-1937.
|
18. |
Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer, 1997, 33(3): 385-391.
|
19. |
黄妩姣, 吴子安, 易四维, 等. 比较不同方法检测血清 CYFRA21-1 对肺癌的临床诊断价值. 广州医学院学报, 2010, 38(1): 44-47.
|
20. |
Kumar A, Cherian SV, Vassallo R, et al. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest, 2018, 154(2): 394-408.
|
21. |
Kohashi Y, Arai T, Sugimoto C, et al. Clinical impact of emphysema evaluated by high-resolution computed tomography on idiopathic pulmonary fibrosis diagnosed by surgical lung biopsy. Respiration, 2016, 92(4): 220-228.
|
22. |
Zhang L, Zhang C, Dong F, et al. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis. BMC Pulm Med, 2016, 16(1): 137.
|